Clavulanate Potassium With Silicon Dioxide (1:1)

Clavulanate Potassium With Silicon Dioxide (1:1) – Beta-Lactamase Inhibitor for Pharma and Veterinary Use

1. Introduction

Clavulanate Potassium With Silicon Dioxide (1:1) is a stabilized blend of potassium clavulanate and silicon dioxide, used widely in pharmaceutical and veterinary drug manufacturing. It acts as a beta-lactamase inhibitor, restoring the efficacy of beta-lactam antibiotics like Amoxicillin against resistant bacteria.

2. Applications

2.1 In human medicine

• Used in combination with Amoxicillin to produce Augmentin formulations

• Treats respiratory, urinary tract, ENT, and skin infections

• Inhibits beta-lactamase enzymes, protecting the antibiotic from degradation

2.2 In veterinary medicine

• Formulated into injectables and oral medications for livestock and companion animals

• Effective against respiratory infections, uterine infections, enteritis, etc.

• Enhances antibiotic effectiveness, reduces resistance, and lowers dosage needed

3. Key advantages

• Ideal 1:1 ratio for stability and ease of blending

• Silicon dioxide prevents caking and improves flowability

• Enhanced shelf life of potassium clavulanate

• Suitable for tablets, capsules, and injectable formulations

4. Product information

• Name: Clavulanate Potassium With Silicon Dioxide (1:1)

• Composition: 50% Potassium Clavulanate + 50% Silicon Dioxide

• Form: Off-white to white powder, free-flowing

• Standards: USP / BP / EP

• Packaging: 5kg aluminum bags or 10–25kg cartons with PE liner

• Origin: China / India

• Storage: Keep tightly sealed in a cool, dry place, away from light and heat

5. Conclusion

Clavulanate Potassium With Silicon Dioxide (1:1) is an essential ingredient for enhancing antibiotic efficacy in both human and veterinary medicine. Its stability, compatibility, and proven performance make it a trusted raw material in modern pharmaceutical manufacturing.